首页> 外文期刊>Journal of Cancer Research and Therapeutics >Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer
【24h】

Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer

机译:血清乳酸脱氢酶水平在小细胞肺癌随访中潜在价值的临床评价

获取原文
           

摘要

Background: Lactate formation is upregulated in tumor cells by lactate dehydrogenase (LDH). High serum LDH level is linked to many malignancies with poorer survival, but tumor LDH has not been well investigated in small cell lung cancer (SCLC). Patients and Methods: The study was performed in 120 cases of SCLC confirmed by pathological examination. The evaluation of treatment response to chemotherapy was based on response evaluation criteria in solid tumors criteria. The serum LDH levels were determined at diagnosis and follow-up visits. The distribution and differences in LDH change and the chemotherapeutic response rate was evaluated by using χ 2 tests. Receiver operating characteristic curves were calculated to select the cut-off level of an increase in LDH indicating significant progression. The correlation of time of serum LDH normalization, time-to-progression (TTP), and overall survival (OS) were analyzed by Pearson correlation. Influence of increasing LDH on survival was calculated using the Kaplan–Meier method. Results: At diagnosis, significant differences in LDH levels were found between the groups with limited or extensive. In contrast to the limited-stage group, the extensive-stage group showed significantly decreased the level of LDH after the first-line chemotherapy. In patients whose diseases progressed, LDH levels were significantly higher in the last 1-month period preceding progression compared with the level at the progression. In the follow-up, we found that prolonging periods of serum LDH normalization were co-related to TTP and OS significantly. An increase in LDH by at least 51.5 U/L was found to be associated to a significantly higher probability of disease progression, and patients with initial increased LDH had a significantly reduced probability of survival. Conclusions: LDH is validated for its potential usefulness as markers for monitoring treatment response in SCLC and also suitable for discriminating between disease and disease-free periods.
机译:背景:乳酸脱氢酶(LDH)在肿瘤细胞中上调乳酸形成。高血清LDH水平与许多恶性肿瘤相关,且生存率较差,但是在小细胞肺癌(SCLC)中尚未对肿瘤LDH进行深入研究。患者和方法:本研究在120例经病理检查证实的SCLC中进行。对化学疗法的治疗反应的评估基于实体肿瘤标准中的反应评估标准。在诊断和随访时确定血清LDH水平。用χ 2 检验评价LDH变化的分布和差异以及化疗反应率。计算接收器的工作特性曲线以选择LDH升高的临界水平,表明明显的进展。通过皮尔森相关性分析了血清LDH正常化时间,进展时间(TTP)和总生存时间(OS)的相关性。使用Kaplan-Meier方法计算LDH的增加对生存的影响。结果:在诊断时,在有限或广泛组之间发现LDH水平存在显着差异。与有限期组相反,广泛期组显示一线化疗后LDH水平明显降低。在疾病进展的患者中,与进展时的水平相比,进展前的最后一个月的LDH水平明显更高。在随访中,我们发现血清LDH正常化的延长时间与TTP和OS显着相关。发现LDH升高至少51.5 U / L与疾病进展的可能性显着相关,而最初LDH升高的患者的生存率则显着降低。结论:LDH已被证实可作为监测SCLC中治疗反应的标志物的潜在用途,也适用于区分疾病和无病期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号